GlassScriptPhysician profile
Marilyn M Raymond
NPI 1316943491
$11,973.45
in general payments reported to CMS, 2019-2025
77 companies · $3,254 in 2025
The $3,254 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $403 · 2021: $940 · 2022: $1,735 · 2023: $2,371 · 2024: $2,658 · 2025: $3,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,231 · Education: $51.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,231.42 |
| Education | $51.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $962.87 | 2019-2025 | Darzalex, Carvykti, Tecvayli |
| Celgene Corporation | $814.57 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $735.94 | 2019-2025 | |
| Daiichi Sankyo INC. | $707.00 | 2021-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $669.01 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $550.99 | 2019-2025 | |
| Incyte Corporation | $550.75 | 2019-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $521.39 | 2021-2025 | Enhertu, Lynparza, Calquence |
| Pfizer INC. | $461.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $416.31 | 2021-2025 | Vpriv, Vonvendi, Iclusig |
| Eisai INC. | $411.38 | 2020-2025 | |
| Glaxosmithkline, LLC. | $387.12 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Genzyme Corporation | $338.22 | 2020-2025 | |
| Seagen INC. | $277.27 | 2019-2023 | Tukysa, Padcev |
| Ipsen Biopharmaceuticals, INC | $255.42 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $234.04 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $230.78 | 2022-2023 | Precisetumor |
| Lilly USA, LLC | $219.05 | 2019-2023 | Retevmo, Jaypirca |
| Astellas Pharma US INC | $211.57 | 2019-2025 | Xtandi, Xospata |
| Pharmacyclics LLC, An Abbvie Company | $208.82 | 2021-2023 | Imbruvica, Epkinly |
| Array Biopharma INC | $174.41 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Genentech USA, INC. | $168.20 | 2019-2025 | Polivy, Tecentriq, Venclexta |
| Jazz Pharmaceuticals INC. | $149.34 | 2021-2025 | |
| Kyowa Kirin, INC. | $149.26 | 2022-2025 | Poteligeo |
| Tersera Therapeutics LLC | $130.50 | 2023-2025 | Zoladex |
| Emd Serono, INC. | $118.82 | 2021-2025 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $106.86 | 2019-2024 | Augtyro |
| Adaptive Biotechnologies Corporation | $99.59 | 2022-2025 | Clonoseq |
| Menarini Silicon Biosystems, INC. | $97.50 | 2024 | |
| Amgen INC. | $92.35 | 2019-2022 | |
| Beigene USA, INC. | $83.66 | 2022-2024 | Brukinsa |
| Blueprint Medicines Corporation | $78.81 | 2023-2025 | Ayvakit |
| Sobi, INC | $76.88 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $70.27 | 2023-2025 | Libtayo, Lynozyfic |
| Gilead Sciences, INC. | $70.19 | 2021-2024 | |
| Adc Therapeutics America, INC. | $58.34 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $58.06 | 2021-2024 | Ultomiris |
| Puma Biotechnology, INC. | $55.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.63 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $44.95 | 2021-2022 | |
| Kite Pharma, INC. | $44.87 | 2024-2025 | Yescarta |
| Mirati Therapeutics, INC. | $43.41 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $43.06 | 2024 | Xpovio |
| Stemline Therapeutics INC. | $42.65 | 2023-2025 | Orserdu |
| Tempus Ai, INC | $41.09 | 2024 | Xt Cdx |
| Aurobindo Pharma USA, INC. | $40.72 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $39.52 | 2022-2025 | Qinlock, Tgct |
| Clovis Oncology, INC. | $34.66 | 2021 | |
| Legend Biotech USA INC. | $32.38 | 2025 | Carvykti |
| Fennec Pharmaceuticals, INC. | $30.00 | 2024 | Pedmark |
| Sumitomo Pharma America, INC. | $29.30 | 2025 | Orgovyx |
| Dova Pharmaceuticals | $26.98 | 2021 | |
| Janssen Scientific Affairs, LLC | $24.96 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $24.49 | 2022 | |
| Springworks Therapeutics, INC. | $23.30 | 2025 | Ogsiveo |
| Heron Therapeutics, INC. | $22.18 | 2021-2022 | |
| Taiho Oncology, INC. | $22.15 | 2021 | |
| Servier Pharmaceuticals LLC | $21.93 | 2022 | |
| Geron Corporation | $21.79 | 2025 | Rytelo |
| Tesaro, INC. | $21.68 | 2019 | |
| Exelixis INC. | $21.52 | 2025 | Cabometyx |
| Delcath Systems | $21.26 | 2025 | Hepzato Kit |
| Recordati_rare_diseases_inc. | $19.71 | 2023 | Sylvant |
| Beone Medicines USA, INC. | $19.53 | 2025 | Brukinsa |
| Cumberland Pharmaceuticals, INC. | $19.49 | 2023 | Sancuso |
| Biocon Biologics INC | $19.44 | 2025 | Ogivri |
| Sirtex Medical INC | $18.05 | 2020 | |
| Tg Therapeutics, INC. | $17.14 | 2021 | |
| Cti Biopharma Corp. | $16.74 | 2023 | Vonjo |
| Kerecis Limited | $15.85 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Azurity Pharmaceuticals, INC. | $15.67 | 2024 | Vivimusta |
| Agios Pharmaceuticals, INC. | $15.39 | 2025 | Pyrukynd |
| Napo Pharmaceuticals INC | $14.79 | 2024 | Gelclair Concentrated Oral Gel |
| Iovance Biotherapeutics, INC. | $7.64 | 2025 | Amtagvi |
| Veracyte, INC. | $4.22 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.